Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02047344

Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC

Non-small Cell Lung Cancer Stage IV Clinical Trial

Official title:
A Single-Arm, Open-Label, Phase II Trial Evaluating the Efficacy, Safety and Pharmacokinetics of Antroquinonol in Patients With Stage IV (Including Pleural Effusion) Non Squamous NSCLC Who Have Failed Two Lines of Anti-Cancer Therapy

Clinical Trial Summary

This is a single arm, open label, Phase II study in KRAS-positive and KRAS-negative patients with stage IV (including pleural effusion) non squamous NSCLC who have failed two lines of anti-cancer therapy. A maximum of 60 evaluable patients with NSCLC will receive antroquinonol, of which 30 patients will be KRAS-positive and 30 patients KRAS-negative. An evaluable patient will have received at least one dose of antroquinonol and have a valid baseline tumor assessment. Enrollment will continue until the target number of evaluable patients has been enrolled.

Clinical Trial Description

1. Progression free survival rate at 12 weeks, defined as the proportion of patients alive and progression free at Week 12. Patients will be progression free if they have no tumor assessments of progressive disease (defined according to RECIST guidelines, version 1.1) at any point from the start of treatment to Week 12.

2. Objective response rate (ORR), defined as the proportion of patients whose best overall response is either CR or PR according to RECIST version 1.1. The best overall response is the best response recorded during the first 12 week treatment cycle.

3. Disease control rate (DCR), defined as the proportion of patients with a documented CR, PR and SD during the first 12 week treatment cycle according to RECIST version 1.1.

4. Duration of overall tumor response (DR), defined as the interval between the date of the first observation of tumor response (CR or PR) and the date of disease progression or death.

5. Progression free survival defined as the time from randomization to objective tumor progression by RECIST version 1.1 or death due to any cause, whichever occurs first.

6. Overall survival (OS) defined as the time from randomization to death from any cause.

7. Time to progression (TTP) defined as the time from randomization to objective tumor progression by RECIST version 1.1. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02047344
Study type Interventional
Source Golden Biotechnology Corporation
Contact
Status Completed
Phase Phase 2
Start date October 2013
Completion date December 7, 2018
View Details
See also
  Status Clinical Trial Phase
Terminated NCT00766246 - Phase II Avastin Trial for Stage IIIB/IV NSCLC Phase 2
Active, not recruiting NCT04108026 - Immunotherapy in Patient With Poor General Condition Phase 2
Active, not recruiting NCT04432207 - A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer Phase 1
Recruiting NCT05598853 - Intrathecal Double Checkpoint Inhibition Phase 1
Not yet recruiting NCT06117644 - The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC
Terminated NCT01348126 - Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer Phase 2/Phase 3
Completed NCT01086254 - SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung Cancer Phase 2
Terminated NCT01798485 - A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC Phase 3
Recruiting NCT06348199 - A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer Phase 3
Not yet recruiting NCT06436144 - Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC Phase 2
Terminated NCT04289259 - Tumor Mutational Burden in Lung Cancer Patients
Active, not recruiting NCT05818449 - Improvement of Personalized Lung Cancer Care Through Digital Connection and Patient Participation (DigiNet) N/A
Completed NCT03526900 - Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis Phase 2
Not yet recruiting NCT06463665 - Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's of Choice Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer (VIRO-25) Phase 2
Completed NCT02176369 - Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial Phase 2
Terminated NCT03275597 - Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition Phase 1
Completed NCT02450539 - A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer Phase 2
Active, not recruiting NCT05055167 - Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLC Phase 2
Not yet recruiting NCT03532698 - Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)
Not yet recruiting NCT03543683 - Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC